VEGFA and neoplasm: The anti-tumour efficacy of these treatments, administered alone and in combination for 2 weeks, was assessed in a VEGF-secreting human head and neck tumour cell line, CAL33, that highly expresses EGFR, established as xenografts (250 mm3) in nude mice.